You can see they have a linear plan for trials then commercialization. This indicates we need announcements about follow-up trials before we can start thinking about commercial partnerships.
Given the presentation was provided at the end of May, that the follow-up studies are either underway or agreed upon, and the length of time field studies take to complete, (Including, I assume waiting for the right time of year), we may be waiting a while for any commercial partnerships to materialise.
This product is exceptional but patience is required. This is a sleeper stock. When the time comes, the market will reflect it's real value. Until then, I would advise against worrying too much about the share price. It could drop to half if the spec space undergoes further pressure. If this happens, I won't mind. This is a long-term hold, 2-3 years at east; probably longer.
BGT Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
